Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 8,548 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 8,548 shares of Stoke Therapeutics stock in a transaction on Friday, December 5th. The shares were sold at an average price of $31.32, for a total value of $267,723.36. Following the completion of the sale, the director directly owned 62,554 shares of the company’s stock, valued at $1,959,191.28. The trade was a 12.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Stoke Therapeutics Stock Down 0.6%

Stoke Therapeutics stock traded down $0.18 during mid-day trading on Friday, hitting $30.87. The company had a trading volume of 602,753 shares, compared to its average volume of 917,923. The business has a fifty day moving average of $28.90 and a 200 day moving average of $19.69. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 46.07 and a beta of 1.14. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. Equities analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on STOK. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Wedbush upped their target price on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. increased their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Monday, November 3rd. Finally, Needham & Company LLC increased their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $31.00.

Institutional Trading of Stoke Therapeutics

Several large investors have recently made changes to their positions in STOK. Generali Investments Management Co LLC purchased a new stake in Stoke Therapeutics during the third quarter valued at about $41,000. BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period. Tower Research Capital LLC TRC increased its stake in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period. Strs Ohio purchased a new position in Stoke Therapeutics in the 3rd quarter worth approximately $150,000. Finally, Osaic Holdings Inc. lifted its position in Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after purchasing an additional 5,427 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.